Basiliximab
From Wikipedia, the free encyclopedia
 |
|
|
Basiliximab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Chimeric/Human |
| Target | CD25 |
| Identifiers | |
| CAS number | |
| ATC code | L04 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C6378H9844N1698O1997S48 |
| Mol. mass | 143801.3 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 7.2 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | ? |
Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody to the IL-2Rα receptor of T cells.[1] It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis Pharmaceuticals product[2] and was approved by the Food and Drug Administration (FDA) in 1998.[3]
It is given in two doses, the first within 2 hours of the start of the transplant operation and the second 4 days after the transplant. These saturate the receptors and prevent T cells from replication and also from activating the B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.
Like the similar drug daclizumab, basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections. In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.
[edit] References & Notes
- ^ IL-2Rα receptor is also known as the CD25 T-cell antigen
- ^ Novartis product page for Simulect (basiliximab for injection) . Retrieved 2005-03-09.
- ^ Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277.
|
|||||||||||||||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
